ADC Therapeutics SA
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $19.25M | $-0.11 | $-0.11 |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | Before market open | $20.85M | $-0.21 | $-0.13 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | $23.06M | $-0.04 | $-0.09 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $15.80M | $-0.30 | $-0.19 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $18.84M | $-0.50 | $-0.25 |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | $23.03M | $-0.36 | $-0.22 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | $16.91M | $-0.29 | $-0.25 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements ADC Therapeutics filed with the SEC
ADC Therapeutics Announces Comprehensive Strategic
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LOTIS - 5: Forest Plot of Progression Free Survival by IRC In favor of ZYNLONTA+R In favor of R - GemOx ITT population, N=420; Data cut off: February 16, 2026. Corporate Presentation | 44
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Strategic Reorganization to Support ZYNLONTA ® Growth Opportunities and Regulatory Priorities
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA ® in Combination with Rituximab in Relapsed or Refractory
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LOTIS - 5 Topline Results Presentation JUNE 3, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Results of operations · EX-99.1 to Form 8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
ADC Therapeutics Announces $60 Million Private
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Results of operations · Unregistered share sale · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
JPMorgan 43 rd Annual Healthcare Conference January 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2024 ZYNLONTA R/R MZL Phase 2 IIT Initial Data Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
April 9, 2024 2024 Research Investor Event
Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
4Q 2023 Earnings Call March 13, 2024 Exhibit 99.2
Results of operations · EX-99.2 to Form 8-K
ADC Therapeutics Business Overview Cowen Conference March 5, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
ADC Therapeutics Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Business Update January 4, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ADC Therapeutics Receives NYSE Notice of Non-Compliance
EX-99.1 to Form 6-K
Morgan Stanley Global Healthcare Conference September 11, 2023
EX-99.1 to Form 6-K
Articles of Association of ADC Therapeutics SA
EX-99.1 to Form 6-K